Status:
COMPLETED
Pharmacological Modulation of Belief Salience
Lead Sponsor:
King's College London
Collaborating Sponsors:
Medical Research Council
Conditions:
Haloperidol
Placebo
Eligibility:
MALE
18-65 years
Phase:
PHASE1
Brief Summary
To provide an initial test of the hypothesis that dopamine mediates the motivational salience of stimuli beyond simple stimulus-reinforcement associations, the researchers propose to undertake a study...
Detailed Description
Delusions in psychiatry are viewed as a form of aberrant belief. Consequently it is important to understand the cognitive and neural processes involved in beliefs to provide insights into how these pr...
Eligibility Criteria
Inclusion
- Healthy males between the ages of 18-65
Exclusion
- History or current psychiatric or neurological illness, history or current serious medical diagnosis, BMI outside of normal/healthy range, smoker over 5 cigarettes per day, recent use of drugs, non-english speaker.
Key Trial Info
Start Date :
June 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2019
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03754062
Start Date
June 1 2017
End Date
September 1 2019
Last Update
October 10 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre for Neuroimaging Sciences
London, United Kingdom, W1T 7NF